Placebo to QVA149

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)

Phase 3

The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01490125

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2011-10-31End: 2012-08-31Updated: 2013-12-24

The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01574651

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2012-05-31End: 2013-04-30Updated: 2014-05-22

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

CompletedNCT01709903

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2012-11-30End: 2014-02-28Updated: 2015-03-17

Related Papers

Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.

2016-10-017 citations

Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study

COPD Journal of Chronic Obstructive Pulmonary Disease2016-08-114 citations

Once-Daily QVA149 Improves Breathlessness in COPD Patients

MD Conference Express2013-07-01